Advertisement

Topics

Tegsedi receives European marketing authorisation approval

08:32 EDT 17 Jul 2018 | EPM Magazine

Akcea Therapeutics and Ionis Pharmaceuticals have announced that Tegsedi (inotersen) has received European marketing authorisation approval for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hATTR

Original Article: Tegsedi receives European marketing authorisation approval

NEXT ARTICLE

More From BioPortfolio on "Tegsedi receives European marketing authorisation approval"

Advertisement
Quick Search
Advertisement
Advertisement